Stryker stock faces lower 2026 outlook after Q3 miss

Stryker reported third-quarter results on Thursday, October 29, and lowered its full-year 2026 outlook after sales and adjusted earnings fell short of the expectations cited in the company's market coverage. The medical-technology group still delivered organic growth and expanded its adjusted operating margin.

What has changed since our last report

The Lang & Schwarz quote is 5.25 percent below the EUR 279.05 level recorded in our October 29 report. Stryker stock traded at EUR 264.40 on Lang & Schwarz at 4:42 p.m. CEST on Friday, October 30, 7.37 percent above the Xetra close of EUR 246.25 on Thursday, October 29. Investors can follow the real-time quote of Stryker Corp stock separately from the company's U.S. dollar listing.

Quarterly growth remained uneven

Net sales rose 7.7 percent year over year to USD 6.52 billion, while organic sales also increased 7.7 percent. MedSurg and Neurotechnology sales advanced 9.2 percent to USD 3.7 billion, compared with 5.7 percent growth to USD 2.9 billion in Orthopaedics, according to Stryker's results release published by Nasdaq.

Reported net earnings fell 12.3 percent to USD 753 million, and reported diluted earnings per share declined to USD 1.96 from USD 2.22 a year earlier. The figures included a USD 293 million goodwill impairment. On an adjusted basis, net earnings increased 10.1 percent to USD 1.4 billion and adjusted earnings per share rose 10.3 percent to USD 3.52. Adjusted operating margin expanded 60 basis points to 26.2 percent.

Lower guidance raises execution pressure

Stryker now expects 2026 organic sales growth of 6.5 percent to 7.0 percent and adjusted diluted earnings per share of USD 14.80 to USD 14.90. The company said its performance fell short of its own expectations, while Chief Executive Kevin Lobo pointed to a solid fourth quarter and momentum heading into 2027. The outlook includes a modestly positive pricing contribution and a slightly favorable foreign-exchange effect if rates remain near current levels.

The revised outlook puts greater emphasis on demand trends and execution in the final quarter. Stryker also repurchased USD 1.0 billion of common stock during the quarter, and its board approved a USD 3.0 billion increase to the existing repurchase authorization.

The S&P 500 market environment provides the broader backdrop for the U.S.-listed medical-technology company.

More news and analyses on Stryker Corp stock are available for investors.